Badger Meter: Project Recovery And Software Growth Support A Buy

Badger Meter is rated a buy, with the view supported by growth prospects and a reasonable valuation. A ramp-up in nine large AMI projects and ongoing digitalization are expected to drive sequential sales growth and margin recovery in 2H FY26 and FY27; expanding recurring SaaS revenue from BEACON and Beyond the Meter is also expected to broaden BMI’s TAM and support margin expansion.

Analysis

The key underwriting question is whether project activity converts into recognized revenue and higher-quality recurring software revenue—not simply whether digital-water demand is attractive. A clustered rollout can produce a near-term revenue step-up but also leave quarterly results exposed to customer deployment schedules, acceptance milestones, and mix; a delay could push the expected recovery out without invalidating the long-run digitization thesis. SaaS expansion would matter most if customer retention, attach rates, and software contribution improve alongside hardware deployments. Those metrics are not supplied, so do not capitalize the TAM narrative as proven earnings durability yet.

Over the next 1–3 months, watch order conversion, backlog/deployment commentary, and gross-margin progression for evidence that the ramp is translating into operating leverage. Over 6–18 months, successful software attachment could support a higher-quality revenue mix; conversely, aggressive pricing or implementation costs could blunt the margin benefit. Competitors such as Xylem and Itron may constrain pricing or compete for municipal budgets, but overlap and win rates need verification. The bullish thesis is falsified by repeated project slippage, weak software attachment/retention, or margins failing to recover despite higher sales. With no valuation, estimates, or price data provided, the buy rating alone is insufficient to establish attractive risk/reward; the signal is moderately constructive, not a basis for chasing.

Key Decisions for Investors

• Keep BMI on a long-entry watchlist; consider initiating only after confirming that project deployments are converting into reported sales and margins, rather than trading the analyst’s forecast in isolation.
• At the next results and guidance update, verify deployment timing, backlog conversion, software attach rates or recurring-revenue growth, and gross-margin trend. Treat missing disclosures as a reason to cap conviction.
• Do not use a peer short as a hedge without evidence of direct bid overlap or relative valuation; monitor Xylem and Itron for competitive pricing and municipal award signals.
• Reassess the thesis if multiple projects slip, software uptake disappoints, or sales growth fails to produce sequential margin improvement; those outcomes would undermine both the near-term recovery and the longer-term quality-of-revenue case.